- Home
- NIVF vs ENVB Comparison
NIVF vs ENVB Comparison
Compare NIVF & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- ENVB
- Stock Information
- Founded
- NIVF 2011
- ENVB 1994
- Country
- NIVF Hong Kong
- ENVB United States
- Employees
- NIVF N/A
- ENVB N/A
- Industry
- NIVF
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- ENVB Health Care
- Exchange
- NIVF NYSE
- ENVB Nasdaq
- Market Cap
- NIVF 3.9M
- ENVB 3.3M
- IPO Year
- NIVF N/A
- ENVB N/A
- Fundamental
- Price
- NIVF $2.11
- ENVB $1.36
- Analyst Decision
- NIVF
- ENVB
- Analyst Count
- NIVF 0
- ENVB 0
- Target Price
- NIVF N/A
- ENVB N/A
- AVG Volume (30 Days)
- NIVF 2.6M
- ENVB 564.4K
- Earning Date
- NIVF 02-16-2025
- ENVB 03-25-2025
- Dividend Yield
- NIVF N/A
- ENVB N/A
- EPS Growth
- NIVF N/A
- ENVB N/A
- EPS
- NIVF N/A
- ENVB N/A
- Revenue
- NIVF $5,679,218.00
- ENVB N/A
- Revenue This Year
- NIVF N/A
- ENVB N/A
- Revenue Next Year
- NIVF N/A
- ENVB N/A
- P/E Ratio
- NIVF N/A
- ENVB N/A
- Revenue Growth
- NIVF N/A
- ENVB N/A
- 52 Week Low
- NIVF $0.11
- ENVB $1.26
- 52 Week High
- NIVF $17.24
- ENVB $657.00
- Technical
- Relative Strength Index (RSI)
- NIVF 76.40
- ENVB 16.91
- Support Level
- NIVF $1.85
- ENVB $1.26
- Resistance Level
- NIVF $2.89
- ENVB $1.70
- Average True Range (ATR)
- NIVF 0.30
- ENVB 0.17
- MACD
- NIVF 0.18
- ENVB 2.34
- Stochastic Oscillator
- NIVF 72.03
- ENVB 12.20
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.